What is the step‑by‑step management of acute decompensated heart failure, including blood pressure‑guided use of diuretics, nitroglycerin, inotropes, vasopressors, oxygen therapy, anticoagulation, beta‑blocker adjustments, and when to consider ultrafiltration or mechanical circulatory support?

Management of Acute Decompensated Heart Failure

Begin immediate IV loop diuretics at a dose equal to or exceeding the patient's chronic oral daily dose (or 20-40 mg IV furosemide if diuretic-naïve), stratify treatment by blood pressure, continue beta-blockers unless in cardiogenic shock, and reserve inotropes/vasopressors only for hypotensive patients with hypoperfusion and elevated filling pressures. 1, 2

Initial Assessment and Stabilization

Immediate Diagnostic Steps

• Assess adequacy of systemic perfusion and volume status
• Obtain ECG, cardiac troponin, and BNP/NT-proBNP to identify acute coronary syndrome and confirm HF diagnosis 1
• Identify precipitating factors: acute coronary syndrome, severe hypertension, arrhythmias, infections, pulmonary embolism, renal failure, or medication/dietary noncompliance 1
• Administer oxygen therapy only if hypoxemic 1

Blood Pressure-Guided Treatment Algorithm

For SBP >90 mmHg (Normotensive/Hypertensive):

• Primary strategy: IV loop diuretics PLUS IV vasodilators 2, 3
• IV nitroglycerin starting at 5 mcg/min (using non-absorbing tubing), titrate by 5 mcg/min every 3-5 minutes up to 20 mcg/min, then increase by 10-20 mcg/min increments 4, 5
• Nitroglycerin is particularly beneficial in hypertensive AHF (SBP >120 mmHg) for rapid symptom relief and improved oxygenation 2, 6
• Critical caveat: Only one-third of eligible patients with SBP >120 mmHg currently receive nitrates—this represents significant underutilization 6

For SBP <90 mmHg with Hypoperfusion:

• IV inotropes (dobutamine 2-20 mcg/kg/min OR milrinone 0.375-0.75 mcg/kg/min) 2
• Add vasopressors (norepinephrine preferred over dopamine, 0.2-1.0 mcg/kg/min) if hypotension persists despite inotropes 2
• Warning: Inotropes increase mortality risk and should be avoided unless patient is symptomatic from hypoperfusion 2

Diuretic Management

Initial Dosing Strategy

• If already on loop diuretics: IV dose must equal or exceed chronic oral daily dose 1, 7
• If diuretic-naïve: Start with 20-40 mg IV furosemide 2
• Administer as intermittent boluses OR continuous infusion—both are equally effective 2
• Begin therapy immediately in the emergency department without delay 1

Escalation for Inadequate Diuresis

When congestion persists despite initial therapy, intensify using: 1

1. Higher doses of loop diuretics (double the dose)
2. Add second diuretic: metolazone, spironolactone, or IV chlorothiazide
3. Switch to continuous infusion of loop diuretic

Important monitoring: Daily weights, strict intake/output, daily electrolytes, BUN, and creatinine during IV diuretic therapy 1

Beta-Blocker Management

Continue beta-blockers in most patients unless hemodynamically unstable or in cardiogenic shock. 1

• In acute decompensation, beta-blockers may require dose reduction but should NOT be discontinued unless cardiogenic shock is present 8
• For new initiation: Wait until volume status optimized and IV diuretics/vasodilators/inotropes discontinued, then start at low dose 1, 7
• Rationale: Abrupt withdrawal worsens outcomes; continuation maintains neurohormonal blockade 8

Anticoagulation

Administer thromboembolism prophylaxis (LMWH or equivalent) to all hospitalized patients unless already anticoagulated or contraindicated. 2, 7

• Mandatory for atrial fibrillation patients (INR 2-3) 8
• Prophylactic dosing for all others to prevent deep venous thrombosis and pulmonary embolism 2

Advanced Therapies

Ultrafiltration

• Consider when: Obvious volume overload refractory to escalating diuretic regimens 7, 9
• May achieve more effective fluid removal than diuretics with potential for reduced rehospitalization 9
• Limitation: Requires further investigation to define optimal patient selection 9

Mechanical Circulatory Support

• Indications for referral: LVEF <25%, NYHA class III-IV despite guideline-directed medical therapy, high predicted 1-2 year mortality, or dependence on continuous IV inotropes 7
• Requires multidisciplinary team evaluation (advanced HF cardiologists, cardiothoracic surgeons, social workers, palliative care) 7
• Timing is critical: Consider early, before end-organ damage develops 10

Invasive Hemodynamic Monitoring

Use pulmonary artery catheter when: 1, 3

• Respiratory distress or impaired perfusion with uncertain filling pressures on clinical exam
• Persistent symptoms despite empiric therapy adjustments
• Systolic pressure remains low with symptoms
• Worsening renal function with therapy
• Requiring parenteral vasoactive agents

Common Pitfalls to Avoid

1. Underdosing diuretics: Initial IV dose must match or exceed oral maintenance dose—starting too low delays decongestion 1
2. Underutilizing vasodilators: Only 33% of eligible hypertensive patients receive nitrates despite clear benefit 6
3. Inappropriate inotrope use: Reserved ONLY for hypotensive patients with hypoperfusion—not for congestion alone 2
4. Stopping beta-blockers: Continue unless cardiogenic shock; dose reduction acceptable but discontinuation worsens outcomes 1, 8
5. Delayed advanced therapy referral: Mechanical support should be considered before irreversible organ damage 10

Discharge Planning

• Transition from IV to oral diuretics with careful dose titration and electrolyte monitoring 1
• Initiate or optimize ACEIs/ARBs and beta-blockers in stable patients before discharge 1, 7
• Monitor for orthostatic hypotension and worsening renal function with medication changes 1